Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech’s SEC reports are packed with clinical data tables, R&D cost breakdowns, and milestone disclosures that can stretch past 200 pages. Finding when a vitiligo study hits Phase II or how much cash runway remains shouldn’t take an entire afternoon.
Stock Titan tackles that problem head-on. Our AI reads every newly posted Edesa Biotech quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the instant they appear on EDGAR. It then highlights what most investors hunt for: trial enrollment updates, government grant inflows, and liquidity ratios—distilled into plain English. Curious about director stock sales? Get Edesa Biotech Form 4 insider transactions real-time alerts so you never miss a trade.
Use the platform to:
- Track Edesa Biotech insider trading Form 4 transactions and spot buying trends before the market reacts.
- Compare quarter-over-quarter R&D spend with one-click Edesa Biotech earnings report filing analysis.
- Review the Edesa Biotech proxy statement executive compensation section without wading through legalese.
Whether you’re asking “How do I understand Edesa Biotech SEC documents with AI?” or searching for “Edesa Biotech executive stock transactions Form 4,” this page delivers. Real-time feeds, AI-powered summaries, and expert context turn dense biotech disclosures into actionable insights you can trust.
BioCardia, Inc. (BCDA) – Form 4 insider transaction
Director Andrew Scott Blank, through the Andy Blank Revocable Living Trust, participated in the company’s 30 June 2025 private placement. The trust purchased 72,289 common shares at $2.075 each and received 72,289 five-year warrants exercisable at $1.95 per share. The transaction was coded “P” (open-market/other purchase) and was executed concurrently with the institutional placement.
Following the purchase, Blank’s indirect holdings stand at 346,023 common shares and 314,522 warrants. No shares were disposed of other than a small 2,035-share adjustment noted as “D.” The filing signals continued insider confidence and modestly increases Blank’s economic exposure by roughly $150 thousand in cash invested (based on disclosed price).
- Transaction date: 30 Jun 2025; filing signed 2 Jul 2025.
- Insider role: Director; Form filed individually.
- All securities are held indirectly via the revocable living trust.
No earnings data or additional corporate developments were included in this filing.
FAQ
What is the current stock price of Edesa Biotech (EDSA)?
What is the market cap of Edesa Biotech (EDSA)?
What is the main focus of Edesa Biotech Inc?
How does Edesa’s approach differ from traditional therapies?
Which therapeutic areas does the company target?
What are the key components of Edesa’s clinical pipeline?
How does Edesa support its clinical development?
What makes Edesa Biotech a notable player in its industry?
Who are the ideal beneficiaries of Edesa’s innovative therapies?
